Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Arena Submits Response to FDA CRL for Lorcaserin: Eisai
January 5, 2012
- CanBas’ CBP501 Receives Orphan Drug Designation from US FDA
January 5, 2012
- SymBio Initiates PII Trials for Relapsed, Refractory Multiple Myeloma Treatment SyB L-0501
December 28, 2011
- Nippon Kayaku Starts Clinical Study for Remicade Biosimilar
December 28, 2011
- Sanofi-aventis Completes Patient Enrollment for Int’l ATLAS Study for Lantus
December 28, 2011
- 2 ARB/CCB Combination Products Enter Top 100 Sales Ranking in 1st Half of FY2011
December 28, 2011
- Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
- Ain Pharmaciez’s Generic Drug Wholesale Subsidiary Showing Steady Growth
December 28, 2011
- Fuji Pharma, Mochida Apply for Japan’s 1st G-CSF Biosimilar
December 27, 2011
- Nippon Kayaku: Pharm Sales Remains Virtually Unchanged in Jun-Nov
December 27, 2011
- Novartis Receives Add’l Approval for Afinitor as 1st pNET Indication in Japan
December 27, 2011
- Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
- Sawai Pharmaceutical Wins Ebastine Patent Dispute
December 26, 2011
- JT to Introduce Anti-HIV Drug Booster from US Company
December 26, 2011
- Toray, JT, Torii Terminate Joint Development of Additional Indication for Nalfurafine
December 26, 2011
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
- Novo Nordisk Pharma Submits NDA for Insulin Degludec
December 26, 2011
- Takeda to Set Up New Unit to Support Investigator-Initiated Research
December 22, 2011
- BMKK, Pfizer Japan Apply for Apixaban for SPAF in Japan
December 22, 2011
- Takeda to Acquire Intellikine to Enhance Oncology Pipeline
December 22, 2011
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…